Aging presents one of the most formidable challenges to human health, with the gradual decline of the hematopoietic system standing as a critical contributor to diminished immune competence and increased vulnerability to disease. Central to this decline are hematopoietic stem cells (HSCs), the foundational units responsible for lifelong blood regeneration and immune cell replenishment. Recent collaborative research between The University of Tokyo, Japan, and St. Jude Children’s Research Hospital, USA, has shed new light on the molecular underpinnings of HSC aging, identifying a non-canonical, non-lethal role for the necroptosis-associated protein MLKL (mixed lineage kinase domain-like protein) in driving mitochondrial dysfunction and stem cell deterioration.
Traditionally, MLKL has been primarily studied within the context of necroptosis, a form of programmed cell death characterized by its inflammatory consequences and dependence on the receptor-interacting protein kinase 3 (RIPK3). However, the new study, published in Nature Communications on April 6, 2026, embarks from an unexpected observation: despite repeated exposure to hematopoietic stress via chemotherapy analogue 5-fluorouracil, aged MLKL-knockout mice display significantly preserved hematopoietic function. Intriguingly, this preservation occurs without measurable differences in stem cell survival, indicating functions of MLKL that transcend its canonical death-inducing roles.
Aging hematopoietic stem cells characteristically lose their capacity for robust self-renewal and balanced lineage differentiation, instead skewing toward overproduction of myeloid lineage cells at the expense of lymphoid populations. This imbalance contributes to the declining adaptive immunity observed in elderly populations. The mechanisms guiding these shifts are multifaceted, involving accumulated DNA damage, chromatin remodeling, chronic low-grade inflammation (inflammaging), and alterations within the bone marrow niche. Yet, precisely how these various forms of cellular stress lead to functional HSC impairment has remained an open question.
In this groundbreaking study, the research team harnessed an array of sophisticated genetic mouse models, including MLKL and RIPK3 knockout strains, alongside engineered reporter mice equipped with a Förster resonance energy transfer (FRET)-based biosensor to monitor real-time MLKL activation. These models allowed unprecedented insight into the spatiotemporal dynamics of MLKL signaling in hematopoietic stem cells subjected to stress conditions designed to mimic aging—such as systemic inflammatory triggers, replication stress, and oncogenic challenges.
Functional assays centered on bone marrow transplantation revealed that MLKL-deficient mice retained a remarkable capacity for hematopoietic regeneration relative to their wild-type counterparts. This regeneration was coupled with preserved mitochondrial integrity, as detailed through high-resolution electron microscopy, mitochondrial membrane potential assays, and comprehensive metabolic profiling. Notably, MLKL activation within stressed HSCs was localized predominantly to the mitochondria, where it did not provoke cell death but rather elicited discrete alterations in mitochondrial structure and function.
These mitochondrial perturbations included disrupted membrane potential—a critical factor for ATP synthesis—alongside morphological abnormalities visible under transmission electron microscopy. Such mitochondrial damage precipitated a decline in cellular energy homeostasis, which correlated with classical markers of stem cell aging, including diminished self-renewal capacity and a shift favoring myeloid differentiation. This insight reveals a pivotal role for MLKL as a stress-responsive factor that directly modulates mitochondrial health, independent of its role in necroptotic pathways.
Crucially, the deletion or pharmacological inhibition of MLKL mitigated these phenotypes, preserving HSC functionality and limiting DNA damage accumulation, despite ongoing exposure to systemic stress. This finding suggests that MLKL acts primarily through organelle-level and post-transcriptional processes rather than by altering gene transcription or chromatin accessibility, as conventional aging theories have emphasized. RNA-sequencing data and assays for transposase-accessible chromatin corroborated this, revealing minimal shifts in gene expression profiles attributable to MLKL status.
From a broader perspective, this work redefines the biological roles of necroptosis-associated proteins, highlighting that non-lethal MLKL signaling exerts profound effects on stem cell aging and mitochondrial dynamics. Rather than serving solely as executors of cell death, MLKL molecules emerge as critical modulators of cellular metabolism and functional longevity within hematopoietic stem cell populations.
The translational implications of these discoveries are significant. Dr. Masayuki Yamashita, the study’s senior author, underscores the potential for targeting MLKL-driven mitochondrial dysfunction to preserve HSC function in clinical contexts marked by hematopoietic stress, such as chemotherapy, radiation therapy, and bone marrow transplantation. Therapeutic strategies may include the development of MLKL inhibitors or agents that bolster mitochondrial resilience, aiming to attenuate stem cell aging and bolster immune competence.
Moreover, the study may catalyze a paradigm shift in our understanding of aging across other adult stem cell systems, prompting investigations into whether similar non-lethal death signal pathways impact organ-specific stem cells and contribute to systemic age-related decline.
In summary, this research provides compelling evidence that MLKL possesses a non-necroptotic function that critically influences mitochondrial health and hematopoietic stem cell aging. By delineating this novel mechanism, the study offers a promising new target for intervention strategies seeking to rejuvenate blood systems and improve outcomes for patients suffering from hematologic conditions and age-associated immune dysfunction.
This work exemplifies the power of interdisciplinary and international collaboration, combining advanced genetic tools, cutting-edge microscopy, and functional hematologic assays to uncover hidden dimensions of stem cell biology. It opens new frontiers not only in stem cell aging research but also in the intricate crosstalk between cell death machinery and mitochondrial dynamics, which may reverberate across diverse fields within life sciences and medicine.
As the population ages globally, understanding and mitigating hematopoietic stem cell decline remains an urgent biomedical challenge. The uncovering of non-lethal MLKL activity as a driver of mitochondrial damage stands as a beacon toward novel therapeutic avenues, potentially transforming clinical approaches to aging hematopoiesis and immune senescence in the years to come.
Subject of Research: Animals
Article Title: Non-necroptotic MLKL function damages mitochondria and promotes hematopoietic stem cell aging
News Publication Date: 6-Apr-2026
Web References:
DOI link to article
References:
Yuta Yamada, Jinjing Yang, Akiho Saiki-Tsuchiya, Yuji Watanabe, Shuhei Koide, Shin Murai, Yuriko Sorimachi, Yu Fukuda, Kenta Sumiyama, Hiroshi Sagara, Hiroyasu Nakano, Keiyo Takubo, Atsushi Iwama, Masayuki Yamashita. “Non-necroptotic MLKL function damages mitochondria and promotes hematopoietic stem cell aging.” Nature Communications, 2026. DOI: 10.1038/s41467-026-71060-4
Image Credits: Dr. Masayuki Yamashita from The University of Tokyo, Japan
Keywords: Hematopoietic stem cells, MLKL, necroptosis, mitochondrial dysfunction, stem cell aging, hematopoiesis, programmed cell death, RIPK3, mitochondrial membrane potential, inflammation, DNA damage, lineage skewing
